These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 21184619)

  • 1. Advances in cancer therapeutics and patient access to new drugs.
    Dranitsaris G; Truter I; Lubbe MS; Amir E; Evans W
    Pharmacoeconomics; 2011 Mar; 29(3):213-24. PubMed ID: 21184619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice?
    Dranitsaris G; Papadopoulos G
    Appl Health Econ Health Policy; 2015 Jun; 13(3):291-302. PubMed ID: 25274258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concern over cost of and access to cancer treatments: A meta-narrative review of nivolumab and pembrolizumab studies.
    da Veiga CRP; da Veiga CP; Drummond-Lage AP
    Crit Rev Oncol Hematol; 2018 Sep; 129():133-145. PubMed ID: 30097232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A global comparison regarding patient access to cancer drugs.
    Jönsson B; Wilking N
    Ann Oncol; 2007 Apr; 18 Suppl 3():iii1-iii77. PubMed ID: 17494969
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs are scarce as mix of programs aims to ease access.
    Brower V
    J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
    [No Abstract]   [Full Text] [Related]  

  • 6. The Role of Humanitarian Donations in Decreasing Preventable Mortality From Cancer in Low-Income Countries: Models to Improve Access to Life-Saving Medicines.
    Garcia-Gonzalez P; Lopes G; Schwartz E; Shulman LN
    J Glob Oncol; 2018 Jul; 4():1-3. PubMed ID: 30084718
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted immunotherapies overtaking emerging oncology market value based growth.
    Jakovljevic MB
    J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
    [No Abstract]   [Full Text] [Related]  

  • 8. In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments.
    Aguiar PN; Adashek JJ; Roitberg F; Noia Barreto CM; Del Giglio A; Lopes GL
    Value Health Reg Issues; 2019 Dec; 20():47-50. PubMed ID: 30856543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient access schemes for high-cost cancer medicines.
    Williamson S
    Lancet Oncol; 2010 Feb; 11(2):111-2. PubMed ID: 20152762
    [No Abstract]   [Full Text] [Related]  

  • 10. Health policy: Putting a price on cancer.
    Sullivan R; Aggarwal A
    Nat Rev Clin Oncol; 2016 Mar; 13(3):137-8. PubMed ID: 26856742
    [No Abstract]   [Full Text] [Related]  

  • 11. Expensive cancer drugs: a comparison between the United States and the United Kingdom.
    Faden RR; Chalkidou K; Appleby J; Waters HR; Leider JP
    Milbank Q; 2009 Dec; 87(4):789-819. PubMed ID: 20021586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perspectives on Cost and Value in Cancer Care.
    Saltz LB
    JAMA Oncol; 2016 Jan; 2(1):19-21. PubMed ID: 26501848
    [No Abstract]   [Full Text] [Related]  

  • 13. Access to expensive anti-cancer drugs.
    Mileshkin L; Sullivan D
    J Law Med; 2011 Dec; 19(2):232-43. PubMed ID: 22319998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can the Spanish care system assume the new costs of medications against cancer?
    Camps C; Caballero C; Sirera R; Blasco A; Cayuela D; Gil M; Badía X
    Clin Transl Oncol; 2008 Feb; 10(2):96-101. PubMed ID: 18258508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to cancer medications in low- and middle-income countries.
    Lopes Gde L; de Souza JA; Barrios C
    Nat Rev Clin Oncol; 2013 Jun; 10(6):314-22. PubMed ID: 23568416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. End of life or end of the road? Are rising cancer costs sustainable? Is it time to consider alternative incentive and funding schemes?
    McGuire A; Drummond M; Martin M; Justo N
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):599-605. PubMed ID: 26176751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Has the time come for metronomics in low-income and middle-income countries?
    André N; Banavali S; Snihur Y; Pasquier E
    Lancet Oncol; 2013 May; 14(6):e239-48. PubMed ID: 23639324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consortium Outlines 3 Solutions to Maximize the Benefit and Affordability of Targeted Cancer Drugs.
    Cancer; 2018 Aug; 124(16):3283. PubMed ID: 30141838
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer Drugs Fund of minimal benefit.
    Burki TK
    Lancet Oncol; 2017 Jun; 18(6):e305. PubMed ID: 28483412
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.